This mouse monoclonal antibody binds to the 65 kDa late antigen (LA) of cytomegalovirus (CMV). It was derived from a mouse immunized with the 65 kDa CMV late antigen. Applications for this antibody include western blot, immunofluorescence, and ELISA for research purposes only.
Vaccine efficacy of FMD virus -like particles like particles like particles ...EuFMD
The European Commission for the Control of Foot-and-Mouth Disease (EuFMD), one of FAO’s oldest Commissions, came into being on the 12th June 1954, with the pledge of the sixth founding member state to the principles of a coordinated and common action against Foot-and-mouth Disease.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Recombinant monoclonal antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
Vaccine efficacy of FMD virus -like particles like particles like particles ...EuFMD
The European Commission for the Control of Foot-and-Mouth Disease (EuFMD), one of FAO’s oldest Commissions, came into being on the 12th June 1954, with the pledge of the sixth founding member state to the principles of a coordinated and common action against Foot-and-mouth Disease.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Recombinant monoclonal antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
This antibody is a rat monoclonal antibody that binds specifically to mouse CX3CL1/Fractalkine, and it can neutralize the bioactivity of mouse CX3CL1/Fractalkine.
Recombinant Human Antibody (dAb HEL4) is capable of binding to Chicken LYZ, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-Chicken LYZ mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-Chicken LYZ mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. HEL4 is highly soluble at concentrations of> or =3 mM, essentially monomeric and resistant to aggregation upon thermodenaturation at concentrations as high as 56 microM.
Recombinant monoclonal antibody to CD70. VL-8-VH is a human antibody that can be potentially used in the treatment of autoimmune and inflammatory disease.
Untargeted metabolomics, namely discovery metabolomics, involves the comparison of the metabolome between the control and test groups, to identify differences between their metabolite profiles which may be relevant to specific biological conditions.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of IL2. under in vitro conditions, IL2-FuP efficiently initiated T-cell activation and stimulated LAKs as well as CTLs. Its potency was superior but not qualitatively different from that of a mixture of anti-EGFR and IL2 This immunocytokine was designed for treating Hodgkin's lymphoma.
MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers.
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts.
Provided is an anti-human CD40 antibody that is substantially antagonistic to a human CD40 antigen on the dendritic cell (DC) surface. And it is an agonistic anti-human CD40 antibody that is expected to have a therapeutic effect higher than those of conventional anti-human CD40 antibodies.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to TNF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of TNF. TNF-FuP provided a weak stimulus for lymphocyte proliferation, but it had no effect on LAK cells. However, it supported activation of Mfs and, to a minor extent, of CTLs. This immunocytokine was designed for treating CD30-positive lymphoma.
The present antibody specifically binds to CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell- mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose.
Recombinant Chimeric (Human/Mouse) Antibody (CHI621) is capable of binding to CD25, expressed in Chinese Hamster Ovary cells (CHO). This chimeric antibody (SDZ CHI621) has been evaluated in a phase I/II clinical study in human renal cadaver transplantation and has shown very promising results.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 IgG to RLI. It was expressed in CHO and purified with affinity chromatography.
Recombinant Humanized monoclonal antibody expressed in CHO binding to Human CCL20. TAB-096CL is an investigational monoclonal antibody that is an antagonist for human CCL20, a chemokine ligand that binds to the CCR6 receptor. The CCL20/CCR6 interaction is implicated in a range of autoimmune diseases.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
This antibody is a rat monoclonal antibody that binds specifically to mouse CX3CL1/Fractalkine, and it can neutralize the bioactivity of mouse CX3CL1/Fractalkine.
Recombinant Human Antibody (dAb HEL4) is capable of binding to Chicken LYZ, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-Chicken LYZ mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-Chicken LYZ mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. HEL4 is highly soluble at concentrations of> or =3 mM, essentially monomeric and resistant to aggregation upon thermodenaturation at concentrations as high as 56 microM.
Recombinant monoclonal antibody to CD70. VL-8-VH is a human antibody that can be potentially used in the treatment of autoimmune and inflammatory disease.
Untargeted metabolomics, namely discovery metabolomics, involves the comparison of the metabolome between the control and test groups, to identify differences between their metabolite profiles which may be relevant to specific biological conditions.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of IL2. under in vitro conditions, IL2-FuP efficiently initiated T-cell activation and stimulated LAKs as well as CTLs. Its potency was superior but not qualitatively different from that of a mixture of anti-EGFR and IL2 This immunocytokine was designed for treating Hodgkin's lymphoma.
MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers.
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts.
Provided is an anti-human CD40 antibody that is substantially antagonistic to a human CD40 antigen on the dendritic cell (DC) surface. And it is an agonistic anti-human CD40 antibody that is expected to have a therapeutic effect higher than those of conventional anti-human CD40 antibodies.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to TNF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of TNF. TNF-FuP provided a weak stimulus for lymphocyte proliferation, but it had no effect on LAK cells. However, it supported activation of Mfs and, to a minor extent, of CTLs. This immunocytokine was designed for treating CD30-positive lymphoma.
The present antibody specifically binds to CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell- mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose.
Recombinant Chimeric (Human/Mouse) Antibody (CHI621) is capable of binding to CD25, expressed in Chinese Hamster Ovary cells (CHO). This chimeric antibody (SDZ CHI621) has been evaluated in a phase I/II clinical study in human renal cadaver transplantation and has shown very promising results.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 IgG to RLI. It was expressed in CHO and purified with affinity chromatography.
Recombinant Humanized monoclonal antibody expressed in CHO binding to Human CCL20. TAB-096CL is an investigational monoclonal antibody that is an antagonist for human CCL20, a chemokine ligand that binds to the CCR6 receptor. The CCL20/CCR6 interaction is implicated in a range of autoimmune diseases.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Cancer cell metabolism: special Reference to Lactate PathwayAADYARAJPANDEY1
Normal Cell Metabolism:
Cellular respiration describes the series of steps that cells use to break down sugar and other chemicals to get the energy we need to function.
Energy is stored in the bonds of glucose and when glucose is broken down, much of that energy is released.
Cell utilize energy in the form of ATP.
The first step of respiration is called glycolysis. In a series of steps, glycolysis breaks glucose into two smaller molecules - a chemical called pyruvate. A small amount of ATP is formed during this process.
Most healthy cells continue the breakdown in a second process, called the Kreb's cycle. The Kreb's cycle allows cells to “burn” the pyruvates made in glycolysis to get more ATP.
The last step in the breakdown of glucose is called oxidative phosphorylation (Ox-Phos).
It takes place in specialized cell structures called mitochondria. This process produces a large amount of ATP. Importantly, cells need oxygen to complete oxidative phosphorylation.
If a cell completes only glycolysis, only 2 molecules of ATP are made per glucose. However, if the cell completes the entire respiration process (glycolysis - Kreb's - oxidative phosphorylation), about 36 molecules of ATP are created, giving it much more energy to use.
IN CANCER CELL:
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
introduction to WARBERG PHENOMENA:
WARBURG EFFECT Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside.
Otto Heinrich Warburg (; 8 October 1883 – 1 August 1970) In 1931 was awarded the Nobel Prize in Physiology for his "discovery of the nature and mode of action of the respiratory enzyme.
WARNBURG EFFECT : cancer cells under aerobic (well-oxygenated) conditions to metabolize glucose to lactate (aerobic glycolysis) is known as the Warburg effect. Warburg made the observation that tumor slices consume glucose and secrete lactate at a higher rate than normal tissues.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
1. antibody kda
• This product is a mouse monoclonal antibody that is capable of
binding to CMV 65 kDa LA.
2. • Specifications
• ImmunogenCMV 65 kDa late antigen
• HostMouse
• DerivationMouse
• TypeMouse antibody
• SpecificityCMV 65 kDa Late Antigen
• Species ReactivityCMV
• CloneJ33G
• ApplicationsCan be useful in applications such as: WB, IF, ELISA
• Target
• Alternative NamesCMV LA; Cytomegalovirus LA; CMV Late Antigen; 65 kDa Late Antigen
• For lab research use only, not for diagnostic, therapeutic or any in vivo human use.